102 related articles for article (PubMed ID: 2082953)
21. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration.
van Loveren-Huyben CM; Engelaar HF; Hermans MB; van der Bom JA; Leering C; Munnichs JM
J Am Geriatr Soc; 1984 Aug; 32(8):584-8. PubMed ID: 6379022
[TBL] [Abstract][Full Text] [Related]
22. Lack of efficacy of hydergine in Alzheimer's disease.
Posner JD; Landsberg L
N Engl J Med; 1991 Jan; 324(3):197-8. PubMed ID: 1984200
[No Abstract] [Full Text] [Related]
23. Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial.
Rouy JM; Douillon AM; Compan B; Wolmark Y
Curr Med Res Opin; 1989; 11(6):380-9. PubMed ID: 2651014
[TBL] [Abstract][Full Text] [Related]
24. Effects of long-term ergoloid mesylates ('Hydergine') administration in healthy pensioners: 5-year results.
Huber F; Köberle S; Prestele H; Spiegel R
Curr Med Res Opin; 1986; 10(4):256-79. PubMed ID: 3780290
[TBL] [Abstract][Full Text] [Related]
25. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia.
Thienhaus OJ; Wheeler BG; Simon S; Zemlan FP; Hartford JT
J Am Geriatr Soc; 1987 Mar; 35(3):219-23. PubMed ID: 3819261
[TBL] [Abstract][Full Text] [Related]
26. Overview of clinical trials of hydergine in dementia.
Schneider LS; Olin JT
Arch Neurol; 1994 Aug; 51(8):787-98. PubMed ID: 8042927
[TBL] [Abstract][Full Text] [Related]
27. Hydergine treatment and psychophysiological measures in primary degenerative dementia.
Kuskowski MA; Morley G; Malone SM; Dysken MW; Okaya A
J Geriatr Psychiatry Neurol; 1990; 3(1):41-7. PubMed ID: 2189430
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy.
Datta KD; Evenson RC; Gannon PJ; Dick EP
Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(1):87-90. PubMed ID: 3299496
[TBL] [Abstract][Full Text] [Related]
29. [Neuropsychological study of decline of attention and drug therapy of patients with Alzheimer's disease].
Tecce JJ; Cattanach L; Boehner-Davis MB; Branconnier RJ; Cole JO
Presse Med; 1983 Dec; 12(48):3155-62. PubMed ID: 6228933
[TBL] [Abstract][Full Text] [Related]
30. Hydergine in Alzheimer's disease.
Baer L; Jenike MA
J Geriatr Psychiatry Neurol; 1991; 4(2):122-3. PubMed ID: 1854422
[No Abstract] [Full Text] [Related]
31. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature.
Hughes JR; Williams JG; Currier RD
J Am Geriatr Soc; 1976 Nov; 24(11):490-7. PubMed ID: 823192
[TBL] [Abstract][Full Text] [Related]
32. A controlled long-term study with ergoloid mesylates (Hydergine) in healthy, elderly volunteers: results after three years.
Spiegel R; Huber F; Köberle S
J Am Geriatr Soc; 1983 Sep; 31(9):549-55. PubMed ID: 6886282
[TBL] [Abstract][Full Text] [Related]
33. Hydergine in senile mental impairment.
Loew DM; Weil C
Gerontology; 1982; 28(1):54-74. PubMed ID: 7037548
[TBL] [Abstract][Full Text] [Related]
34. A double-blind evaluation of 'Hydergine' and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home.
Thibault A
Curr Med Res Opin; 1974; 2(8):482-7. PubMed ID: 4217240
[No Abstract] [Full Text] [Related]
35. Evaluation of an analogue of somatostatin (L363,586) in Alzheimer's disease.
Cutler NR; Haxby JV; Narang PK; May C; Burg C; Reines SA
N Engl J Med; 1985 Mar; 312(11):725. PubMed ID: 2858052
[No Abstract] [Full Text] [Related]
36. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease.
Wesseling H; Agoston S; Van Dam GB; Pasma J; DeWit DJ; Havinga H
N Engl J Med; 1984 Apr; 310(15):988-9. PubMed ID: 6366565
[No Abstract] [Full Text] [Related]
37. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
[TBL] [Abstract][Full Text] [Related]
38. Ergoloid mesylates for senile dementias: unanswered questions.
Hollister LE; Yesavage J
Ann Intern Med; 1984 Jun; 100(6):894-8. PubMed ID: 6372566
[TBL] [Abstract][Full Text] [Related]
39. Effect of ergot alkaloids on serum prolactin in non-psychotic organic brain syndrome of the elderly.
Gross RJ; Eisdorfer CE; Schiller HS; Cox G
Exp Aging Res; 1979 Aug; 5(4):293-302. PubMed ID: 520386
[TBL] [Abstract][Full Text] [Related]
40. Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients.
Sörgel F; Abisch E; Dennler HJ; Lang E
Eur J Clin Pharmacol; 1984; 26(1):133-5. PubMed ID: 6714287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
